MEDNAX Inc (MD) Shares Bought by Aristotle Capital Boston LLC
Aristotle Capital Boston LLC boosted its stake in MEDNAX Inc (NYSE:MD) by 11.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 333,468 shares of the company’s stock after acquiring an additional 35,200 shares during the quarter. Aristotle Capital Boston LLC’s holdings in MEDNAX were worth $15,560,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of MEDNAX during the 3rd quarter worth $1,243,000. Kemnay Advisory Services Inc. purchased a new stake in MEDNAX in the 3rd quarter valued at about $1,296,000. Capital Fund Management S.A. purchased a new stake in MEDNAX in the 3rd quarter valued at about $982,000. Renaissance Technologies LLC raised its holdings in MEDNAX by 242.3% in the 3rd quarter. Renaissance Technologies LLC now owns 577,200 shares of the company’s stock valued at $26,932,000 after buying an additional 408,577 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in MEDNAX by 224.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 9,078 shares of the company’s stock valued at $424,000 after buying an additional 6,277 shares during the period. 98.16% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts recently issued reports on MD shares. BMO Capital Markets reduced their price objective on shares of MEDNAX from $48.00 to $43.00 and set a “market perform” rating on the stock in a report on Friday, November 2nd. ValuEngine lowered shares of MEDNAX from a “sell” rating to a “strong sell” rating in a report on Thursday, November 1st. UBS Group started coverage on shares of MEDNAX in a report on Friday, November 16th. They issued a “sell” rating and a $37.00 price objective on the stock. Bank of America upgraded shares of MEDNAX from an “underperform” rating to a “neutral” rating and reduced their price objective for the company from $60.00 to $50.00 in a report on Tuesday, September 18th. Finally, Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a report on Wednesday. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $51.20.
MEDNAX (NYSE:MD) last released its earnings results on Thursday, November 1st. The company reported $0.94 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.03). The firm had revenue of $896.60 million during the quarter, compared to analyst estimates of $908.15 million. MEDNAX had a net margin of 9.50% and a return on equity of 10.45%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.87 earnings per share. On average, sell-side analysts forecast that MEDNAX Inc will post 3.51 earnings per share for the current fiscal year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Recommended Story: What is the NASDAQ?
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.